These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25593038)

  • 21. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer.
    Stallone G; Cormio L; Netti GS; Infante B; Selvaggio O; Fino GD; Ranieri E; Bruno F; Prattichizzo C; Sanguedolce F; Tortorella S; Bufo P; Grandaliano G; Carrieri G
    Cancer Res; 2014 Aug; 74(16):4230-8. PubMed ID: 24950910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammation: gearing the journey to cancer.
    Kundu JK; Surh YJ
    Mutat Res; 2008; 659(1-2):15-30. PubMed ID: 18485806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
    Gerstenbluth RE; Seftel AD; MacLennan GT; Rao RN; Corty EW; Ferguson K; Resnick MI
    J Urol; 2002 May; 167(5):2267-70. PubMed ID: 11956490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
    Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
    Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer.
    Elkahwaji JE
    Res Rep Urol; 2012 Dec; 5():1-10. PubMed ID: 24400229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
    Lu Y; Wang J; Xu Y; Koch AE; Cai Z; Chen X; Galson DL; Taichman RS; Zhang J
    Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Aggarwal RR; Ryan CJ; Chan JM
    Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype.
    Smith AM; Findlay VJ; Bandurraga SG; Kistner-Griffin E; Spruill LS; Liu A; Golshayan AR; Turner DP
    Carcinogenesis; 2012 Mar; 33(3):572-80. PubMed ID: 22232738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer.
    Gatti G; Quintar AA; Andreani V; Nicola JP; Maldonado CA; Masini-Repiso AM; Rivero VE; Maccioni M
    Prostate; 2009 Sep; 69(13):1387-97. PubMed ID: 19496069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung cancer and inflammation: interaction of chemokines and hnRNPs.
    Tauler J; Mulshine JL
    Curr Opin Pharmacol; 2009 Aug; 9(4):384-8. PubMed ID: 19570713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators.
    Ben-Baruch A
    Semin Cancer Biol; 2006 Feb; 16(1):38-52. PubMed ID: 16139507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
    Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
    Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
    König JE; Senge T; Allhoff EP; König W
    Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
    Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
    J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin 8 and the male genital tract.
    Lotti F; Maggi M
    J Reprod Immunol; 2013 Nov; 100(1):54-65. PubMed ID: 23611586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammation and prostate cancer: the role of interleukin 6 (IL-6).
    Nguyen DP; Li J; Tewari AK
    BJU Int; 2014 Jun; 113(6):986-92. PubMed ID: 24053309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.